NCT05109143 is a NA clinical trial of Indomethacin suppository in Pancreatoduodenectomy, sponsored by Institute of Liver and Biliary Sciences, India.

Who is sponsoring NCT05109143?

NCT05109143 is sponsored by Institute of Liver and Biliary Sciences, India.

What drugs are being tested in NCT05109143?

Interventions in NCT05109143: Indomethacin suppository, Standard Medical Treatment.

What condition does NCT05109143 study?

NCT05109143 studies Pancreatoduodenectomy.

Is NCT05109143 still recruiting?

NCT05109143 is currently completed. Last updated 6 July 2022.

Last reviewed 2022-07-06 · How we verify

NCT05109143

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Rectal Indomethacin in Prevention of Post-operative Pancreatitis After Pancreaticoduodenectomy

Completed NA Last updated 6 July 2022

What this trial tests

NA trial testing Indomethacin suppository in Pancreatoduodenectomy in 44 participants. Completed in 31 May 2022.

Timeline

17 October 2020

Primary endpoint
30 April 2022

31 May 2022

Quick facts

Lead sponsor	Institute of Liver and Biliary Sciences, India
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	44
Start date	17 October 2020
Primary completion	30 April 2022
Estimated completion	31 May 2022
Sites	1 location across India

Drugs / interventions tested

Indomethacin suppository — full drug profile →
Standard Medical Treatment — full drug profile →

Conditions studied

Pancreatoduodenectomy — all drugs for Pancreatoduodenectomy →

Sponsor

Institute of Liver and Biliary Sciences, India

Who can join

Adults 18 to 80, any sex, with Pancreatoduodenectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pancreatico-duodenectomy is one of the commonly performed procedure for periampullary/distal cholangio/head of pancreas carcinoma. Post operative pancreatitis is an emerging concept, recently being studied as one of the most important contributing factor of Post-operative pancreatic fistula, which is one of the major complication of pancreatoduodenectomy. Rectal indomethacin, a type of non-steroidal anti-inflammatory drug, when given in a single dose has been shown to prevent pancreatitis in patients undergoing ERCP. In this study, we will be administering rectal indomethacin at the time of induction of anesthesia to the experimental arm of the study and compare the results in terms of incidence of post-operative pancreatitis in the two groups.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Indomethacin suppository

Trials testing the same drug.

NCT06623513 — Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis · Phase 2 · not yet recruiting
NCT05722548 — Efficacy of Rectal Indomethacin in Prevention of Post-pancreatectomy Acute Pancreatitis · Phase 2 · unknown
NCT05381428 — Prophylaxis of Post-ERCP Acute Pancreatitis · Phase 3 · completed
NCT04964180 — Rectal Indomethacin Versus Intraperitoneal Lidocaine for Analgesia After Laparoscopic Cholecystectomy · NA · completed

Other recruiting trials for Pancreatoduodenectomy

Currently open trials in the same condition.

NCT06953193 — Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia · NA · recruiting
NCT06283160 — METabolomic and Immune PROfiling in the Development of Pancreatic Fistulas After cepHalic duodEnopancreatectomy · recruiting

Other Institute of Liver and Biliary Sciences, India trials

Trials by the same sponsor.

NCT07480005 — To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies · recruiting
NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07465471 — Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. · NA · not yet recruiting
NCT07433881 — Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis · not yet recruiting
NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05109143 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Liver and Biliary Sciences, India
Last refreshed: 6 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05109143.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing